Revenue Estimates Analysis: Amicus Therapeutics, Inc. (NASDAQ:FOLD)


Amicus Therapeutics, Inc. (NASDAQ:FOLD) will report its next earnings on Feb 24 – Feb 28 (Est.). The company reported the earnings of $-0.33/Share in the last quarter where the estimated EPS by analysts was $-0.32/share. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -3.1%.

Many analysts are providing their Estimated Earnings analysis for Amicus Therapeutics, Inc. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $-0.32/share. These analysts have also projected a Low Estimate of $-0.38/share and a High Estimate of $-0.26/share.

Some buy side analysts are also providing their Analysis on Amicus Therapeutics, Inc., where 3 analysts have rated the stock as Strong buy, 3 analysts have given a Buy signal, 2 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 8 Analysts reported that the Price Target for Amicus Therapeutics, Inc. might touch $17 high while the Average Price Target and Low price Target is $12.38 and $9 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Amicus Therapeutics, Inc. got Initiated on 18-May-16 where investment firm BofA/Merrill Initiated the stock to Buy.

Amicus Therapeutics, Inc. closed its last trading session at $8.32 with the loss of -21.75%. The Market Capitalization of the company stands at 926.57 Million. The Company has 52-week high of $11.02 and 52-week low of $4.98. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -20.47% where SMA50 and SMA200 are -15.99% and -8.73% respectively. The Company Touched its 52-Week High on Dec 2, 2015 and 52-Week Low on Jun 27, 2016.

The Relative Volume of the company is 5.77 and Average Volume (3 months) is 2.14 million. Amicus Therapeutics, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -20.5%. The Return on Equity (ROE) value stands at -55.4%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Amicus Therapeutics, Inc. currently shows a Weekly Performance of -27.59%, where Monthly Performance is -7.26%, Quarterly performance is -6.6%, 6 Months performance is -9.33% and yearly performance percentage is -39.33%. Year to Date performance value (YTD perf) value is -32.89%. The Stock currently has a Weekly Volatility of 6.42% and Monthly Volatility of 7.32%.